WFRF:(Prezioso L)
Sökning: WFRF:(Prezioso L) > Outcome of COVID-19...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04199naa a2200913 4500 | |
| 001 | oai:prod.swepub.kib.ki.se:152185839 | |
| 003 | SwePub | |
| 008 | 240701s2023 | |||||||||||000 ||eng| | |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1521858392 URI |
| 024 | 7 | a https://doi.org/10.3389/fimmu.2023.11250302 DOI |
| 040 | a (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Busca, A4 aut |
| 245 | 1 0 | a Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry |
| 264 | c 2023-02-24 | |
| 264 | 1 | b Frontiers Media SA,c 2023 |
| 520 | a The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT.MethodsThis multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022.ResultsThe median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53).ConclusionsMortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection. | |
| 700 | 1 | a Salmanton-Garcia, J4 aut |
| 700 | 1 | a Marchesi, F4 aut |
| 700 | 1 | a Farina, F4 aut |
| 700 | 1 | a Seval, GC4 aut |
| 700 | 1 | a Van Doesum, J4 aut |
| 700 | 1 | a De Jonge, N4 aut |
| 700 | 1 | a Bahr, NC4 aut |
| 700 | 1 | a Maertens, J4 aut |
| 700 | 1 | a Meletiadis, J4 aut |
| 700 | 1 | a Fracchiolla, NS4 aut |
| 700 | 1 | a Weinbergerova, B4 aut |
| 700 | 1 | a Verga, L4 aut |
| 700 | 1 | a Racil, Z4 aut |
| 700 | 1 | a Jimenez, M4 aut |
| 700 | 1 | a Glenthoj, A4 aut |
| 700 | 1 | a Blennow, Ou Karolinska Institutet4 aut |
| 700 | 1 | a Tanase, AD4 aut |
| 700 | 1 | a Schonlein, M4 aut |
| 700 | 1 | a Prezioso, L4 aut |
| 700 | 1 | a Khanna, N4 aut |
| 700 | 1 | a Duarte, RF4 aut |
| 700 | 1 | a Zak, P4 aut |
| 700 | 1 | a Nucci, M4 aut |
| 700 | 1 | a Machado, M4 aut |
| 700 | 1 | a Kulasekararaj, A4 aut |
| 700 | 1 | a Espigado, I4 aut |
| 700 | 1 | a De Kort, E4 aut |
| 700 | 1 | a Susana, JMRS4 aut |
| 700 | 1 | a Marchetti, M4 aut |
| 700 | 1 | a Magliano, G4 aut |
| 700 | 1 | a Falces-Romero, I4 aut |
| 700 | 1 | a Ilhan, O4 aut |
| 700 | 1 | a Ammatuna, E4 aut |
| 700 | 1 | a Zompi, S4 aut |
| 700 | 1 | a Tsirigotis, P4 aut |
| 700 | 1 | a Antoniadou, A4 aut |
| 700 | 1 | a Zambrotta, GPM4 aut |
| 700 | 1 | a Nordlander, Au Karolinska Institutet4 aut |
| 700 | 1 | a Karlsson, LK4 aut |
| 700 | 1 | a Hanakova, M4 aut |
| 700 | 1 | a Dragonetti, G4 aut |
| 700 | 1 | a Cabirta, A4 aut |
| 700 | 1 | a Venemyr, CB4 aut |
| 700 | 1 | a Grafe, S4 aut |
| 700 | 1 | a Van Praet, J4 aut |
| 700 | 1 | a Tragiannidis, A4 aut |
| 700 | 1 | a Petzer, V4 aut |
| 700 | 1 | a Lopez-Garcia, A4 aut |
| 700 | 1 | a Itri, F4 aut |
| 700 | 1 | a Groh, A4 aut |
| 700 | 1 | a Gavriilaki, E4 aut |
| 700 | 1 | a Dargenio, M4 aut |
| 700 | 1 | a Rahimli, L4 aut |
| 700 | 1 | a Cornely, OA4 aut |
| 700 | 1 | a Pagano, L4 aut |
| 710 | 2 | a Karolinska Institutet4 org |
| 773 | 0 | t Frontiers in immunologyd : Frontiers Media SAg 14, s. 1125030-q 14<1125030-x 1664-3224 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:152185839 |
| 856 | 4 8 | u https://doi.org/10.3389/fimmu.2023.1125030 |
Hitta via bibliotek
- Frontiers in immunology (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
Hitta mer i SwePub
- Av författaren/redakt...
- Busca, A
- Salmanton-Garcia ...
- Marchesi, F
- Farina, F
- Seval, GC
- Van Doesum, J
- visa fler...
- De Jonge, N
- Bahr, NC
- Maertens, J
- Meletiadis, J
- Fracchiolla, NS
- Weinbergerova, B
- Verga, L
- Racil, Z
- Jimenez, M
- Glenthoj, A
- Blennow, O
- Tanase, AD
- Schonlein, M
- Prezioso, L
- Khanna, N
- Duarte, RF
- Zak, P
- Nucci, M
- Machado, M
- Kulasekararaj, A
- Espigado, I
- De Kort, E
- Susana, JMRS
- Marchetti, M
- Magliano, G
- Falces-Romero, I
- Ilhan, O
- Ammatuna, E
- Zompi, S
- Tsirigotis, P
- Antoniadou, A
- Zambrotta, GPM
- Nordlander, A
- Karlsson, LK
- Hanakova, M
- Dragonetti, G
- Cabirta, A
- Venemyr, CB
- Grafe, S
- Van Praet, J
- Tragiannidis, A
- Petzer, V
- Lopez-Garcia, A
- Itri, F
- Groh, A
- Gavriilaki, E
- Dargenio, M
- Rahimli, L
- Cornely, OA
- Pagano, L
- visa färre...
- Artiklar i publikationen
- Frontiers in imm ...
- Av lärosätet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
